1. Home
  2. ATCH vs THAR Comparison

ATCH vs THAR Comparison

Compare ATCH & THAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATCH
  • THAR
  • Stock Information
  • Founded
  • ATCH 2022
  • THAR 2017
  • Country
  • ATCH United States
  • THAR United States
  • Employees
  • ATCH N/A
  • THAR N/A
  • Industry
  • ATCH
  • THAR Biotechnology: Pharmaceutical Preparations
  • Sector
  • ATCH
  • THAR Health Care
  • Exchange
  • ATCH Nasdaq
  • THAR Nasdaq
  • Market Cap
  • ATCH 3.2M
  • THAR 3.3M
  • IPO Year
  • ATCH N/A
  • THAR 2022
  • Fundamental
  • Price
  • ATCH $0.21
  • THAR $1.51
  • Analyst Decision
  • ATCH
  • THAR Strong Buy
  • Analyst Count
  • ATCH 0
  • THAR 1
  • Target Price
  • ATCH N/A
  • THAR $17.00
  • AVG Volume (30 Days)
  • ATCH 7.7M
  • THAR 26.3K
  • Earning Date
  • ATCH 05-16-2025
  • THAR 05-12-2025
  • Dividend Yield
  • ATCH N/A
  • THAR N/A
  • EPS Growth
  • ATCH N/A
  • THAR N/A
  • EPS
  • ATCH 2.67
  • THAR N/A
  • Revenue
  • ATCH N/A
  • THAR N/A
  • Revenue This Year
  • ATCH N/A
  • THAR N/A
  • Revenue Next Year
  • ATCH N/A
  • THAR N/A
  • P/E Ratio
  • ATCH $0.08
  • THAR N/A
  • Revenue Growth
  • ATCH N/A
  • THAR N/A
  • 52 Week Low
  • ATCH $0.18
  • THAR $0.95
  • 52 Week High
  • ATCH $83.99
  • THAR $6.39
  • Technical
  • Relative Strength Index (RSI)
  • ATCH 33.79
  • THAR 54.61
  • Support Level
  • ATCH $0.19
  • THAR $1.41
  • Resistance Level
  • ATCH $0.23
  • THAR $1.64
  • Average True Range (ATR)
  • ATCH 0.02
  • THAR 0.11
  • MACD
  • ATCH 0.02
  • THAR 0.01
  • Stochastic Oscillator
  • ATCH 38.18
  • THAR 63.86

About ATCH AtlasClear Holdings Inc. Common Stock

AtlasClear Holdings Inc is a fintech company. Its goal is to build a cutting-edge technology-enabled financial services firm that would create a more efficient platform for trading, clearing, settlement, and banking of evolving and innovative financial products with a focus on financial services firms. It is a fintech-driven business-to-business platform that expects to power innovation in fintech, investing, and trading. The company believes it is positioned to provide a modern, mission-critical suite of solutions to its clients, enabling them to reduce their transaction costs and compete more effectively in their businesses.

About THAR Tharimmune Inc.

Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.

Share on Social Networks: